WO2009096709A2 - Bone cement with anion - Google Patents

Bone cement with anion Download PDF

Info

Publication number
WO2009096709A2
WO2009096709A2 PCT/KR2009/000426 KR2009000426W WO2009096709A2 WO 2009096709 A2 WO2009096709 A2 WO 2009096709A2 KR 2009000426 W KR2009000426 W KR 2009000426W WO 2009096709 A2 WO2009096709 A2 WO 2009096709A2
Authority
WO
WIPO (PCT)
Prior art keywords
anion
bone cement
phosphate
time
added
Prior art date
Application number
PCT/KR2009/000426
Other languages
French (fr)
Korean (ko)
Other versions
WO2009096709A3 (en
Inventor
Kug Sun Hong
Hyun Seung Yu
Jeong Seop Lee
Dong Wook Kim
In Sun Cho
Shin Tae Bae
Hyun Suk Jung
Original Assignee
Snu R & Db Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Snu R & Db Foundation filed Critical Snu R & Db Foundation
Publication of WO2009096709A2 publication Critical patent/WO2009096709A2/en
Publication of WO2009096709A3 publication Critical patent/WO2009096709A3/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L27/46Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/0047Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L24/0073Composite materials, i.e. containing one material dispersed in a matrix of the same or different material with a macromolecular matrix
    • A61L24/0084Composite materials, i.e. containing one material dispersed in a matrix of the same or different material with a macromolecular matrix containing fillers of phosphorus-containing inorganic compounds, e.g. apatite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00Materials or treatment for tissue regeneration
    • A61L2430/02Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants

Definitions

  • the present invention relates to anion-substituted bone cement, and more particularly, it is easy to simultaneously adjust the setting time and injection time, which are the most basic characteristics of bone cement that can be used in a syringe, so that users have sufficient procedure time during surgery. It relates to bone cement substituted with an anion.
  • Bone cement is a substance that can form artificial bones that can replace human bones, and is also referred to as calcium phosphate cement because it mainly contains phosphoric acid and calcium.
  • the bone cement is composed of dry ingredients, which are compounds containing calcium and phosphate sources, and mixed with a hardening solution to form a paste in a state similar to toothpaste. It is to use the process of fixing to hydroxyapatite.
  • One of the most important conditions for bone cement is to have the proper injection time and setting time along with the property that can be injected through the syringe, that is, injection property.
  • the easiest way to control the injection time and setting time is to control the amount of curing liquid used.
  • the curing liquid is not enough, not only the problem of injection property, but also the injection time and setting time is too short, there is a limit to use as a structural material in orthopedic and dental.
  • a hardening accelerator additive to the curing liquid to provide an injection time and proper setting time to allow sufficient procedure time while maintaining the amount of curing liquid to have sufficient injectability. can see.
  • the present invention it is possible to inject through the needle of the syringe by giving an adequate flowability by adjusting the rate of the curing reaction by adding an anion to the dry components or phosphate ions containing a compound containing a calcium source and a phosphate source
  • This provides bone cement that is capable of injecting time (injection time) is sufficient and the setting time can be properly adjusted.
  • a compound capable of supplying anions added to the compound including the calcium source and the phosphate source calcium carbonate (CaCO 3 ), calcium sulfate (CaSO 4 ), barium sulfate (BaSO 4 ), sodium fluoride (NaF), and the like.
  • CaCO 3 calcium carbonate
  • CaSO 4 calcium sulfate
  • BaSO 4 barium sulfate
  • NaF sodium fluoride
  • it is a compound containing anions such as CO 3 2- , SO 4 2- , F ⁇ , PO 4 3- , and HPO 4 2- .
  • the addition amount of such a compound is good for 0.1-30 weight part with respect to 100 weight part of dry components.
  • the curing solution containing the phosphate ion of the present invention means an aqueous solution in which soluble phosphate and emulsifier dissolved in distilled water.
  • Soluble phosphates include diammonium hydrogen phosphate (NH 4 ) 2 HPO 4 ), ammonium dihydrogen phosphate (NH 4 H 2 PO 4 ), sodium phosphate monobasic (NaH) 2 PO 4 ), sodium hydrogen phosphate (Na 2 HPO 4 ), sodium phosphate tribasic (Na 3 PO 4 ), potassium phosphate dibasic (K 2 HPO 4 ), phosphoric acid Potassium phosphate monobasic (KH 2 PO 4 ), dimethyl phosphate (C 2 H 7 PO 4 ), monomagnesium phosphate (Mg (H 2 PO 4 ) 2 ), magnesium phosphate dibasic (magnesium phosphate dibasic, MgHPO 4 ), lithium dihydrogen phosphate (LiH 2 PO 4 ), lithium phosphate (Lithim phosphate, LiPO 4 ), calcium hydrogen orthophosphate hydrate (CaHPO 4 ⁇ 2H 2 O ), Calcium hydrogen orthopho sphate, CaHPO 4
  • sodium phosphate monobasic NaH2PO4
  • sodium phosphate Na 2 HPO 4
  • sodium phosphate tribasic Na 3 PO 4
  • potassium phosphate dibasic K 2 HPO 4
  • potassium phosphate Monobasic potassium phosphate monobasic
  • the emulsifier increases the viscosity of the paste when the paste is mixed with the dry ingredients and the curing solution. If the emulsifier does not enter the cured liquid, the dry ingredient and the cured liquid are mixed and injected into the human body, and the viscosity may be too low, causing the paste to be released by the blood and roam along the blood vessel. In addition, when injected into the human body is the best when the viscosity of the toothpaste, without the emulsifier it is difficult to obtain that viscosity.
  • the compound of the dry component and a feed material of an anion such as calcium carbonate may be mixed.
  • the calcium carbonate is dissolved in the curing liquid to serve as a source material for providing CO 3 2- ions.
  • the reason for adding anion in the present invention is added for the purpose of delaying the curing of bone cement, depending on the actual use case may be added to promote the curing of bone cement.
  • the amount of anion added to the bone cement of the present invention should be considered in order to secure sufficient injectable time and appropriate control of the setting time.
  • the amount is too small, it is difficult to substantially expect the effect of adding anion, If the amount is too large, it causes a problem of excessive delay of bone cement hardening time.
  • the amount of addition is preferably 0.1 to 30 g when the volume of distilled water which is a solvent of the cured liquid is 100 ml.
  • the injectable start time should exceed 4 minutes, and the longer the injectable last time is better.
  • the last possible injection time is too long, it will adversely affect the setting time, so the time interval between the initial setting time and the last setting time is about 5 minutes is sufficient, so it is desirable to properly control the last injection time within this range. .
  • pH 8.3 to pH 6.0 are preferred based on the pH change amount of the curing liquid.
  • the anion is further dissolved by further dissolving compounds containing anions such as CO 3 2- , SO 4 2- , F ⁇ , PO 4 3- , and HPO 4 2- in the cured solution containing the phosphate ions thus prepared, or Blow the gas that can add anion into the curing solution.
  • anions such as CO 3 2- , SO 4 2- , F ⁇ , PO 4 3- , and HPO 4 2- in the cured solution containing the phosphate ions thus prepared, or Blow the gas that can add anion into the curing solution.
  • the present invention is sufficient to inject the injection time (injection time) by delaying the curing rate of bone cement through the addition of anion to the dry components or phosphate ions containing a compound containing a calcium source and a phosphate source It is useful to secure the setting time and to adjust the setting time appropriately.
  • 1 is an X-ray diffraction graph according to the curing time of bone cement cured using a curing liquid to which TTCP and DCPD are used as dry components of bone cement and CO 3 2- anion is added thereto.
  • FIG. 2 is a graph obtained by infrared spectroscopy of bone cement according to the amount of CO 3 2- anion added.
  • (A) shows that when the pH of the cured solution is 7.5 due to the low addition of CO 3 2- anion, (b) is cured. It shows the case where CO 3 2- anion was added until the pH of the liquid no longer decreased.
  • 3 is an electron micrograph before (a) and after curing (b) of the present invention bone cement curing.
  • a compound including a calcium source and a phosphate source that is, a dry ingredient, is mixed with TTCP and DCPD in a molar ratio of 1: 1, milled for 1 to 7 days using anhydrous ethanol, and then used by freeze drying.
  • This powder is 0.1 to 1000 mu m in size and uses completely dried.
  • the cured solution was thoroughly stirred with 1 g of Na 2 HPO 4 in 100 g of distilled water, 1 g of carboxymethyl cellulose was added thereto, dissolved by heating, and used after cooling completely.
  • exemplary clerical script anion is added in a stylized way that blowing CO 2 gas into the hardening liquid, the by measuring the pH of, measuring the amount of the added CO 2 gas produced in the hardening liquid is not possible to add CO 3 2- anions We indirectly know the amount of.
  • the total setting time is approximately 5 to 6 minutes, and the initial time required for the setting as a whole, while maintaining almost the same level as that of the comparative example without CO 3 2- ions being added. It can be seen that a sufficient delay of the last time can be obtained, thus ensuring sufficient time for the procedure.

Abstract

Disclosed is bone cement including dry ingredients as a calcium source and a phosphate source containing at least one type of compound, a hardening solution obtained by dissolving a phosphate and an emulsifying agent in water, and anion added to at least one of the dry ingredients and the hardening solution. The bone cement of the present invention can be used in an injector that allows the setting time and the injection time to be easily and simultaneously adjusted such that sufficient surgical operating time can be provided to a user during operation.

Description

음이온이 치환된 골 시멘트Anion-substituted bone cement
본 발명은 음이온이 치환된 골 시멘트에 관한 것으로, 보다 상세하게는 주사기에 넣어서 사용할 수 있는 골 시멘트의 가장 기초적인 특성인 세팅 시간과 인젝션 시간을 동시에 쉽게 조절하여 수술 시 사용자들이 충분한 시술 시간을 가질 수 있도록 한 음이온이 치환된 골 시멘트에 관한 것이다.The present invention relates to anion-substituted bone cement, and more particularly, it is easy to simultaneously adjust the setting time and injection time, which are the most basic characteristics of bone cement that can be used in a syringe, so that users have sufficient procedure time during surgery. It relates to bone cement substituted with an anion.
골 시멘트(bone cement)는 사람의 뼈를 대체할 수 있는 인공뼈를 구성할 수 있는 물질이며, 인산과 칼슘을 주성분으로 하므로 인산칼슘 시멘트(calcium phosphate cement)라고도 한다. 이러한 골 시멘트는 크게 칼슘 소스와 인산염 소스를 포함하는 화합물인 건식 성분들을 경화액과 혼합하여 치약과 비슷한 상태의 페이스트로 만들고, 이 페이스트를 주사기를 통해 시술부위에 짜 넣어 뼈와 유사한 고체 인산칼슘인 하이드록시아파타이트로 정착되는 과정을 이용하는 것이다.Bone cement is a substance that can form artificial bones that can replace human bones, and is also referred to as calcium phosphate cement because it mainly contains phosphoric acid and calcium. The bone cement is composed of dry ingredients, which are compounds containing calcium and phosphate sources, and mixed with a hardening solution to form a paste in a state similar to toothpaste. It is to use the process of fixing to hydroxyapatite.
골 시멘트가 갖추어야 할 가장 중요한 조건 중의 하나는 주사기를 통해 주입할 수 있는 성질, 즉 주입성의 확보와 함께 적절한 인젝션 시간과 세팅 시간을 가지도록 하는 것이다. One of the most important conditions for bone cement is to have the proper injection time and setting time along with the property that can be injected through the syringe, that is, injection property.
골 시멘트에 있어서 인젝션 시간과 세팅 시간을 조절하는 가장 손쉬운 방법은 사용하는 경화액의 양을 조절하는 것이다. 하지만 이 경우, 경화액이 충분하지 않다면 주입성에 문제가 생길 뿐 아니라 인젝션 시간과 세팅 시간이 너무 짧아 정형외과 및 치과에서의 구조적 재료로 사용하는 데 한계가 있다. 이 문제의 해결을 위해 충분한 주입성을 가질 수 있도록 경화액의 양을 유지하면서, 충분한 시술 시간을 가질 수 있는 인젝션 시간과 적절한 세팅 시간을 제공하기 위해 경화액에 경화 가속 첨가물을 첨가하는 방법을 생각해 볼 수 있다. For bone cement, the easiest way to control the injection time and setting time is to control the amount of curing liquid used. However, in this case, if the curing liquid is not enough, not only the problem of injection property, but also the injection time and setting time is too short, there is a limit to use as a structural material in orthopedic and dental. To solve this problem, consider adding a hardening accelerator additive to the curing liquid to provide an injection time and proper setting time to allow sufficient procedure time while maintaining the amount of curing liquid to have sufficient injectability. can see.
즉, 주입성을 확보하기 위해 경화액의 양을 늘리거나 셀룰로오즈 계통의 첨가물을 넣어주기도 하였으나, 그 양이 지나치게 많아지면 적절한 세팅 시간을 얻을 수가 없는 문제점이 있다. 물론 이때, 경화액에 첨가하는 경화 가속 첨가물의 양을 늘리면 적절한 인젝션 시간과 세팅 시간을 얻을 수 있지만, 온도가 내려가면 첨가된 경화 가속 첨가물이 침전되는 등 또 다른 문제점이 야기된다.In other words, although the amount of the curing liquid is increased or an cellulose-based additive is added to secure the injection property, if the amount is too large, an appropriate setting time cannot be obtained. Of course, at this time, by increasing the amount of the curing acceleration additives added to the curing liquid to obtain an appropriate injection time and setting time, another problem occurs, such as precipitation of the added curing acceleration additives when the temperature is lowered.
따라서 본 발명은 위에서 언급한 문제점을 야기하지 않는 범위 내에서 경화액이나 셀룰로오즈 계통의 첨가물, 그리고 경화 가속 첨가물의 양을 임의로 선택하면서, 여기에 덧붙여 음이온을 건식 성분이나 경화액 중에 첨가하는 방법을 통해 충분한 주입성을 지니고, 인젝션 시간이 충분하고, 세팅시간이 적절하도록 조절할 수 있는 골 시멘트를 제공하는 데 그 목적이 있다.Accordingly, the present invention provides a sufficient amount through the method of adding an anion to the dry component or the curing liquid, in addition to selecting the amount of the curing liquid, the cellulose-based additives, and the curing accelerator additive within the range which does not cause the above-mentioned problems. The object is to provide bone cement that is injectable, has sufficient injection time, and can be adjusted to set the time appropriately.
상기의 목적을 달성하기 위하여, 본 발명에 의하면, 칼슘소스와 인산염소스를 포함하는 화합물인 건식성분, 가용성인산염과 유화제를 용해하여 얻은 경화액, 및 상기 건식성분과 경화액 중 적어도 한쪽에 더 첨가되는 음이온을 포함하는 것을 특징으로 하는 음이온이 포함된 골 시멘트가 제공된다.In order to achieve the above object, according to the present invention, a dry component which is a compound containing a calcium source and a phosphate source, a curing liquid obtained by dissolving a soluble phosphate and an emulsifier, and further added to at least one of the dry component and the curing liquid Provided is a bone cement containing anion, characterized in that it comprises anion.
본 발명에 의하면 칼슘 소스와 인산염 소스를 포함하는 화합물인 건식 성분들이나 인산 이온이 포함된 경화액에 음이온을 첨가하여 경화반응의 속도를 조절함으로써 충분한 흐름성을 부여함으로써 주사기의 바늘을 통해 주입이 가능하여 주입 가능 시간(인젝션 시간)이 충분하고, 세팅 시간을 적절하게 조절할 수 있는 골 시멘트를 제공한다. According to the present invention, it is possible to inject through the needle of the syringe by giving an adequate flowability by adjusting the rate of the curing reaction by adding an anion to the dry components or phosphate ions containing a compound containing a calcium source and a phosphate source This provides bone cement that is capable of injecting time (injection time) is sufficient and the setting time can be properly adjusted.
상기한 음이온이 첨가된 칼슘 소스와 인산염 소스를 포함하는 화합물인 건식 성분(들)은 입자 크기가 전형적으로는 0.1 내지 1000㎛ 정도의 범위이며, 이들은 단일의 인산칼슘계 화합물이나 또는 2개 이상의 화합물들로 존재할 수 있다.The dry ingredient (s), which is a compound comprising a calcium source and a phosphate source to which the anion is added, typically has a particle size in the range of about 0.1 to 1000 μm, which may be a single calcium phosphate compound or two or more compounds. May exist.
칼슘 소스와 인산염 소스를 포함하는 화합물로는, MCPM(인산 일칼슘 일수화물, Ca(H2PO4)2·H2O), MCPA(인산 일캄슘, Ca(H2PO4)2), DCPD(인산 이칼슘 이수화물, 블러샤이트 또는 CaHPO4·2H2O), ACP(무정질 인산 칼슘 또는 Ca3(PO4)2·H2O), DCPA(인산 이칼슘, 모네타이트 또는 CaHPO4), α-TCP와 β-TCP(인산 삼칼슘 또는 Ca3(PO4)2), TTCP(인산 사칼슘 또는 Ca4(PO4)2O), 수산화 칼슘(Ca(OH)2), 산화 칼슘(CaO), HA(하이드록시 아파타이트 또는 Ca10(PO4)6(OH)2) 등을 예로 들 수 있지만 이에 제한되지 않는다.Examples of the compound including a calcium source and a phosphate source include MCPM (monium phosphate monohydrate, Ca (H 2 PO 4 ) 2 H 2 O), MCPA (monium calcium phosphate, Ca (H 2 PO 4 ) 2 ), DCPD (dicalcium phosphate dihydrate, blushite or CaHPO 4 · 2H 2 O), ACP (amorphous calcium phosphate or Ca 3 (PO 4 ) 2 · H 2 O), DCPA (dicalcium phosphate, monite or CaHPO 4 ), α-TCP and β-TCP (tricalcium phosphate or Ca 3 (PO 4 ) 2 ), TTCP (tetracalcium phosphate or Ca 4 (PO 4 ) 2O ), calcium hydroxide (Ca (OH) 2 ), oxidation Examples include, but are not limited to, calcium (CaO), HA (hydroxy apatite or Ca 10 (PO 4 ) 6 (OH) 2 ), and the like.
그리고, 이러한 칼슘 소스와 인산염 소스를 포함하는 화합물에 첨가되는 음이온을 공급할 수 있는 화합물로는 탄산칼슘(CaCO3), 황산칼슘(CaSO4), 황산바륨(BaSO4), 불화소다(NaF) 등과 같이 CO3 2-, SO4 2-, F-, PO4 3-, HPO4 2- 등의 음이온이 포함된 화합물이다. 이러한 화합물의 첨가량은 건식 성분 100 중량부에 대해 0.1 내지 30 중량부가 좋다.In addition, as a compound capable of supplying anions added to the compound including the calcium source and the phosphate source, calcium carbonate (CaCO 3 ), calcium sulfate (CaSO 4 ), barium sulfate (BaSO 4 ), sodium fluoride (NaF), and the like. Likewise, it is a compound containing anions such as CO 3 2- , SO 4 2- , F , PO 4 3- , and HPO 4 2- . The addition amount of such a compound is good for 0.1-30 weight part with respect to 100 weight part of dry components.
그리고 본 발명의 인산 이온이 포함된 경화액은 증류수에 가용성 인산염과 유화제를 녹인 수용액을 의미한다. And the curing solution containing the phosphate ion of the present invention means an aqueous solution in which soluble phosphate and emulsifier dissolved in distilled water.
가용성 인산염으로는 인산 암모늄 이염기성(diammonium hydrogen phosphate, (NH4)2HPO4), 인산 이수소 암모늄(ammonium dihydrogen phosphate, NH4H2PO4), 인산나트륨 일염기(monosodium hydrogen phosphate monobasic, NaH2PO4), 인산나트륨 이염기(disodium hydrogen phosphate, Na2HPO4), 인산트리나트륨(Sodium phosphate tribasic, Na3PO4), 인산칼륨 이염기성(potassium phosphate dibasic, K2HPO4), 인산칼륨 일염기성(potassium phosphate monobasic, KH2PO4), 다이메틸포스페이트(dimethyl phosphate, C2H7PO4), 모노마그네슘 인산염(monomagnesium phosphate, Mg(H2PO4)2), 마그네슘 인산염 이염기(magnesium phosphate dibasic, MgHPO4), 리튬 디수소 인산염 (Lithium dihydrogen phosphate, LiH2PO4), 리튬 인산염(Lithim phosphate, LiPO4), 칼슘수소인산염 수화물(calcium hydrogen orthophosphate hydrate, CaHPO4·2H2O), 칼슘수소인산염(Calcium hydrogen orthophosphate, CaHPO4), 칼슘메타포스페이트(Calcium metaphosphate, CaP2O6), 비정질 인산칼슘(amorphous calcium phosphate, Ca3(PO4)2) 등이 있는데, 이 중에서 인산나트륨 일염기(monosodium hydrogen phosphate monobasic, NaH2PO4), 인산나트륨 이염기(disodium hydrogen phosphate, Na2HPO4), 인산트리나트륨(Sodium phosphate tribasic, Na3PO4), 인산칼륨 이염기성(potassium phosphate dibasic, K2HPO4), 인산칼륨 일염기성 (potassium phosphate monobasic, KH2PO4)이 경화액에 대한 용해도가 높아 바람직하다. Soluble phosphates include diammonium hydrogen phosphate (NH 4 ) 2 HPO 4 ), ammonium dihydrogen phosphate (NH 4 H 2 PO 4 ), sodium phosphate monobasic (NaH) 2 PO 4 ), sodium hydrogen phosphate (Na 2 HPO 4 ), sodium phosphate tribasic (Na 3 PO 4 ), potassium phosphate dibasic (K 2 HPO 4 ), phosphoric acid Potassium phosphate monobasic (KH 2 PO 4 ), dimethyl phosphate (C 2 H 7 PO 4 ), monomagnesium phosphate (Mg (H 2 PO 4 ) 2 ), magnesium phosphate dibasic (magnesium phosphate dibasic, MgHPO 4 ), lithium dihydrogen phosphate (LiH 2 PO 4 ), lithium phosphate (Lithim phosphate, LiPO 4 ), calcium hydrogen orthophosphate hydrate (CaHPO 4 · 2H 2 O ), Calcium hydrogen orthopho sphate, CaHPO 4 ), Calcium metaphosphate (CaP 2 O 6 ), amorphous calcium phosphate (Ca 3 (PO 4 ) 2 ), etc. Among these, sodium phosphate monobasic , NaH2PO4), sodium phosphate (Na 2 HPO 4 ), sodium phosphate tribasic (Na 3 PO 4 ), potassium phosphate dibasic (K 2 HPO 4 ), potassium phosphate Monobasic (potassium phosphate monobasic, KH 2 PO 4 ) is preferred because of high solubility in the curing liquid.
유화제는 건식성분과 경화액을 섞어서 페이스트를 만들었을 때, 페이스트의 점성을 높여주는 역할을 한다. 만약 경화액에 유화제가 들어가지 않는다면 건식성분과 경화액을 섞어 인체에 주입 시, 점성이 너무 낮아 혈액에 의해 페이스트가 풀려 혈관을 따라 돌아다닐 가능성이 있는데, 이런 문제를 해결하기 위해 첨가하는 것이다. 또한 인체에 주입하려면 치약 정도의 점성일 때가 가장 좋은데, 유화제가 없으면 그 정도의 점성을 얻기가 어렵다. The emulsifier increases the viscosity of the paste when the paste is mixed with the dry ingredients and the curing solution. If the emulsifier does not enter the cured liquid, the dry ingredient and the cured liquid are mixed and injected into the human body, and the viscosity may be too low, causing the paste to be released by the blood and roam along the blood vessel. In addition, when injected into the human body is the best when the viscosity of the toothpaste, without the emulsifier it is difficult to obtain that viscosity.
유화제로는 폴리옥시에틸렌 또는 폴리옥시프로필렌 중합체 또는 이들의 공중합체, 예로써 폴리에틸렌 글라이콜 및 폴리프로필렌 글라이콜; 여러 가지 천연 중합체들, 예를 들면 아라비아 검, 구아르 검, 카라기닌, 트라가칸트 검, 펙틴, 전분, 젤라틴, 카제인, 덱스트린, 셀룰로오스; 비이온성 셀룰로오스 에터르, 예를 들면 메틸셀룰로오스, 에틸셀룰로오스, 하이드록시 메틸셀룰로오스, 하이드록시 에틸셀룰로오스, 카르복시 메틸셀룰로오스, 카르복시 에틸셀룰로오스 및 하이드록시 프로필셀룰로오스, 추가의 셀룰로오스들, 예를 들면 카르복시 메틸셀룰로오스 나트륨, 카르복시 메틸셀룰로오스 칼슘, 카르복시메틸 전분 등이 있다. Emulsifiers include polyoxyethylene or polyoxypropylene polymers or copolymers thereof, such as polyethylene glycol and polypropylene glycol; Various natural polymers such as gum arabic, guar gum, carrageenan, tragacanth gum, pectin, starch, gelatin, casein, dextrin, cellulose; Nonionic cellulose ethers such as methyl cellulose, ethyl cellulose, hydroxy methyl cellulose, hydroxy ethyl cellulose, carboxy methyl cellulose, carboxy ethyl cellulose and hydroxy propyl cellulose, further celluloses such as carboxy methyl cellulose sodium , Carboxy methyl cellulose calcium, carboxymethyl starch and the like.
즉, 본 발명에서 칼슘 소스나 인산염 소스가 되는 건식성분의 화합물에 음이온을 첨가하는 방법으로는 상기 건식성분의 화합물과 탄산칼슘과 같은 음이온의 공급물질을 혼합하여 사용할 수 있다. 이 경우 상기 탄산칼슘은 경화액 중에 용해되어 CO3 2- 이온을 제공하는 소스물질로 작용하게 되는 것이다.That is, in the present invention, as a method of adding an anion to a dry component that is a calcium source or a phosphate source, the compound of the dry component and a feed material of an anion such as calcium carbonate may be mixed. In this case, the calcium carbonate is dissolved in the curing liquid to serve as a source material for providing CO 3 2- ions.
또한, 음이온 공급물질을 경화액에 첨가하는 방법을 생각해 볼 수 있는데 이때에는 가스상태의 음이온 공급물질, 예를 들면 CO3 2- 이온을 공급하기 위한 음이온 공급물질로 CO2 가스를 경화액 중에 일정량 불어넣어 주는 방법이 있다. 또 다른 방법으로는 경화액에 가용성인 음이온 공급물질을 화합물 형태로 첨가하는 방법이 있다. In addition, a method of adding an anion feed material to the curing liquid may be considered, in which an amount of CO 2 gas is added to the curing liquid as an anion feed material for supplying a gaseous anion feed material, for example, CO 3 2- ions. There is a way to infuse. Another method is to add a soluble anion feeder in the form of a compound to the curing liquid.
한편, 본 발명에서 음이온을 첨가하는 이유는 골 시멘트의 경화를 지연시킬 목적으로 첨가하는데, 실제 사용 예의 경우에 따라서는 골 시멘트의 경화를 촉진시키기 위하여 첨가할 수도 있다.On the other hand, the reason for adding anion in the present invention is added for the purpose of delaying the curing of bone cement, depending on the actual use case may be added to promote the curing of bone cement.
그리고, 본 발명의 골 시멘트에 첨가되는 음이온의 첨가량은 충분한 인젝션 가능시간의 확보와 세팅 시간의 적절한 조절을 위하여 고려되어야 하는데, 그 양이 지나치게 적으면 음이온 첨가 효과를 실질적으로 기대하기 어렵고, 반면에 그 양이 지나치게 많을 경우 골 시멘트 경화시간의 과다 지연의 문제를 야기하게 된다.In addition, the amount of anion added to the bone cement of the present invention should be considered in order to secure sufficient injectable time and appropriate control of the setting time. When the amount is too small, it is difficult to substantially expect the effect of adding anion, If the amount is too large, it causes a problem of excessive delay of bone cement hardening time.
경화액에 가용성인 음이온 공급물질을 화합물 형태로 첨가하는 경우 그 첨가량은 경화액의 용매인 증류수의 부피를 100 ml로 했을 경우에는 0.1 내지 30g이 적당하다.When the soluble anion feed material is added to the cured liquid in the form of a compound, the amount of addition is preferably 0.1 to 30 g when the volume of distilled water which is a solvent of the cured liquid is 100 ml.
골 시멘트의 인젝션 가능시간과 전체 세팅시간을 고려하면 인젝션가능 시작시간이 4분을 초과하는 것이 좋고 인젝션 가능 마지막시간은 길면 길수록 좋다. 그러나, 인젝션 가능 마지막시간이 지나치게 길면 세팅시간에 나쁜 영향을 미치므로 초기 세팅시간과 마지막 세팅시간과의 시간 간격이 5분 정도이면 충분하므로 이 범위내에서 인젝션 가능 마지막시간을 적절히 제어하는 것이 바람직하다.Considering the injectable time of the bone cement and the total setting time, the injectable start time should exceed 4 minutes, and the longer the injectable last time is better. However, if the last possible injection time is too long, it will adversely affect the setting time, so the time interval between the initial setting time and the last setting time is about 5 minutes is sufficient, so it is desirable to properly control the last injection time within this range. .
본 발명자의 실험에 따르면 CO3 2- 이온을 첨가하기 위하여는 경화액의 pH변화량을 기준으로 볼 때 pH 8.3 내지 pH 6.0 정도가 바람직하다.According to the experiments of the present inventors, in order to add CO 3 2- ions, pH 8.3 to pH 6.0 are preferred based on the pH change amount of the curing liquid.
이렇게 준비된 인산 이온이 포함된 경화액에 CO3 2-, SO4 2-, F-, PO4 3-, HPO4 2- 등의 음이온이 포함된 화합물을 추가로 녹여서 음이온을 첨가시키거나, 해당 음이온을 첨가시켜 줄 수 있는 가스를 경화액에 불어 넣어준다. The anion is further dissolved by further dissolving compounds containing anions such as CO 3 2- , SO 4 2- , F , PO 4 3- , and HPO 4 2- in the cured solution containing the phosphate ions thus prepared, or Blow the gas that can add anion into the curing solution.
상기한 바와 같이, 본 발명은 칼슘 소스와 인산염 소스를 포함하는 화합물인 건식성분들이나 인산이온이 포함된 경화액에 음이온 첨가를 통해 골 시멘트의 경화속도를 지연시킴으로써 주입 가능 시간(인젝션 시간)을 충분히 확보함과 동시에 세팅 시간을 적절히 조절하는 것이 가능한 유용한 것이다.As described above, the present invention is sufficient to inject the injection time (injection time) by delaying the curing rate of bone cement through the addition of anion to the dry components or phosphate ions containing a compound containing a calcium source and a phosphate source It is useful to secure the setting time and to adjust the setting time appropriately.
도 1은 TTCP와 DCPD를 골 시멘트의 건식 성분으로 하고, CO3 2- 음이온을 첨가시킨 경화액을 이용해 경화시킨 골 시멘트의 경화 시간에 따른 X선 회절그래프이다.1 is an X-ray diffraction graph according to the curing time of bone cement cured using a curing liquid to which TTCP and DCPD are used as dry components of bone cement and CO 3 2- anion is added thereto.
도 2는 CO3 2- 음이온의 첨가량에 따른 골 시멘트의 적외선 분광 분석법에 의한 그래프로서, (a)는 CO3 2- 음이온을 적게 첨가하여 경화액의 pH가 7.5인 경우, (b)는 경화액의 pH가 더 이상 내려가지 않을 때까지 CO3 2- 음이온을 첨가한 경우를 도시한 것이다.FIG. 2 is a graph obtained by infrared spectroscopy of bone cement according to the amount of CO 3 2- anion added. (A) shows that when the pH of the cured solution is 7.5 due to the low addition of CO 3 2- anion, (b) is cured. It shows the case where CO 3 2- anion was added until the pH of the liquid no longer decreased.
도 3은 본 발명 골 시멘트 경화 전(a)과 경화 후(b)의 전자 현미경 사진이다. 3 is an electron micrograph before (a) and after curing (b) of the present invention bone cement curing.
이하에 실시예를 통해 본 발명을 더욱 상세히 설명하기로 한다. 다만 본 발명의 범위가 아래의 실시예로 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to Examples. However, the scope of the present invention is not limited to the following examples.
기본적으로 칼슘소스와 인산염소스를 포함하는 화합물, 즉 건식 성분은 TTCP와 DCPD를 1:1의 몰비로 혼합하여 미디어를 무수 에탄올로 하여 1 내지 7일 동안 밀링한 후, 동결 건조하여 사용한다. 이 분말은 0.1 내지 1000㎛ 크기이며, 완전히 건조된 것을 사용한다.Basically, a compound including a calcium source and a phosphate source, that is, a dry ingredient, is mixed with TTCP and DCPD in a molar ratio of 1: 1, milled for 1 to 7 days using anhydrous ethanol, and then used by freeze drying. This powder is 0.1 to 1000 mu m in size and uses completely dried.
경화액은 증류수 100g에 Na2HPO4 1g을 철저히 교반한 후, 카르복시메틸셀룰로오스 1g을 넣어 열을 가해 녹인 다음, 완전히 식힌 후 사용하였다. 그리고 실시예서 음이온은 CO2 가스를 경화액에 불어넣어 주는 방법으로 첨가시켰으며, 첨가된 CO2 가스의 양을 측정하는 것은 불가능하기에 만들어진 경화액의 pH를 측정하여 첨가된 CO3 2- 음이온의 양을 간접적으로 알도록 하였다.The cured solution was thoroughly stirred with 1 g of Na 2 HPO 4 in 100 g of distilled water, 1 g of carboxymethyl cellulose was added thereto, dissolved by heating, and used after cooling completely. And exemplary clerical script anion is added in a stylized way that blowing CO 2 gas into the hardening liquid, the by measuring the pH of, measuring the amount of the added CO 2 gas produced in the hardening liquid is not possible to add CO 3 2- anions We indirectly know the amount of.
모든 비교예와 실시예에 대해서 다음과 같은 방법으로 세팅 시간과 인젝션 시간을 측정하였다. 즉, 세팅 시간은 37도, 30% 상대 습도의 항온기에서 1g의 건식 성분과 1.8㎖의 경화액을 비이커에 넣은 후, 주걱으로 30 초간 골고루 교반하여 길모어(gilmore needle)로 측정하였다. 시간 측정은 건식 성분과 경화액을 섞을 때를 시작 시간으로 하였다. 인젝션 시간은 건식 성분 3g과 경화액 3ml를 수술장의 온도와 비슷한 20도로 모두 냉각시킨 후, 30 초간 주걱으로 철저히 교반한 후, 주사기로 빨아올려 직접 짜보면서 측정하였다.For all comparative examples and examples, the setting time and the injection time were measured in the following manner. That is, the setting time was measured by a gilmore needle by mixing 1 g of dry ingredients and 1.8 ml of a curing liquid in a beaker in a thermostat of 37 degrees and 30% relative humidity in a beaker, and then evenly stirring for 30 seconds with a spatula. The time measurement was taken as the start time when the dry component and the curing liquid were mixed. Injection time was measured by cooling the dry ingredients 3g and 3ml of the curing liquid to 20 degrees similar to the operating room temperature, thoroughly stirred with a spatula for 30 seconds, and then squeezed with a syringe to squeeze directly.
(비교예)(Comparative Example)
상기한 건식 성분과, CO2 가스를 불어 넣어주지 않은 경화액을 사용하여 세팅 시간과 인젝션 시간을 측정하였다. 이 경우 경화액의 pH는 8.6 내지 9.0이었으며, 세팅 시간과 인젝션 시간에 관한 상세내용은 표 1에 나타내었다.Using the above dry component and a hardening liquid are not blown into the CO 2 gas were measured setting time and the injection time. In this case, the pH of the curing liquid was 8.6 to 9.0, and the details of the setting time and the injection time are shown in Table 1.
(실시예 1 내지 5)(Examples 1 to 5)
경화액에 CO3 2- 음이온을 첨가하기 위해 CO2 가스를 그 양을 달리하여 불어 넣어 주면서 실시간으로 pH를 측정하여 pH가 8.0, 7.5, 7.0, 6.5, 완전히 포화된 pH의 경화액을 각각 제조하였다. 상세한 세팅 시간과 인젝션 시간은 표 1에 나타내었다. In order to add CO 3 2- anion to the curing liquid, the amount of CO 2 gas was blown in different amounts, and the pH was measured in real time, thereby preparing a curing liquid having a pH of 8.0, 7.5, 7.0, 6.5, and fully saturated pH, respectively. It was. Detailed setting time and injection time are shown in Table 1.
표 1에 도시한 바로부터, CO3 2- 이온이 첨가되지 않은 비교예의 경우에는 4분후부터 인젝션이 가능하여 인젝션 가능 마지막시간이 8.5분으로 4.5분 정도가 인젝션 가능시간이었다. 이에 반하여, 본 발명의 실시예 1 내지 5에서는 CO3 2- 이온의 양이 증가함에 따라 인젝션 가능 시작시간이 4.5분으로 지연되기 시작하여 최대 9분까지 지연되는 것을 알 수 있다. 그리고, 인젝션 가능 마지막시간도 점차 지연되어 최대 21분까지 지연된다는 사실도 확인할 수 있다. As shown in Table 1, in the comparative example in which CO 3 2- ions were not added, injection was possible after 4 minutes, and the last possible injection time was 8.5 minutes, which was about 4.5 minutes. On the contrary, in Examples 1 to 5 of the present invention, it can be seen that as the amount of CO 3 2- ions increases, the start time of injectable starts to be delayed to 4.5 minutes and is delayed up to 9 minutes. In addition, the last possible injection time is also gradually delayed up to 21 minutes can be seen that.
이러한 결과로부터, 본 발명에 따르면 인젝션에 필요한 시간을 충분히 확보함에 의해 조급한 시술과정에서의 실수를 방지하고 정밀한 시술을 시간적 여유를 가지고 할 수 있는 이점이 있음을 알 수 있다. From these results, it can be seen that according to the present invention, by sufficiently securing the time required for injection, it is possible to prevent mistakes in the hasty procedure and to perform precise procedures with time.
그리고, 세팅시간에 있어서도, 본 발명의 실시예들에 있어서는 전체 세팅시간이 대략 5~6분으로 CO3 2- 이온이 첨가되지 않은 비교예와 거의 같은 수준을 유지하면서도 전체적으로 세팅에 필요한 초기시간과 마지막시간을 크게 지연시키는 결과를 얻을 수 있어 시술시간의 충분한 확보가 가능하다는 것을 알 수 있다.In addition, even in the setting time, in the embodiments of the present invention, the total setting time is approximately 5 to 6 minutes, and the initial time required for the setting as a whole, while maintaining almost the same level as that of the comparative example without CO 3 2- ions being added. It can be seen that a sufficient delay of the last time can be obtained, thus ensuring sufficient time for the procedure.
첨부한 도면을 참조하면, 모든 경우에, 도 1과 같이, 골 시멘트가 경화함에 따라 TTCP 와 DCPD의 혼합물이 하이드록시아파타이트로 변해가는 것을 볼 수 있었다. 도 2를 통해 CO3 2- 음이온이 치환된 하이드록시아파타이트가 경화물로 생성됨을 알 수 있다. 또한 도 3으로부터, 모든 경우에 있어 경화가 진행함에 따라 침상의 하이드록시아파타이트가 생성되어 크로스링크(crosslinking)에 의해 골 시멘트가 경화됨을 알 수 있다.Referring to the accompanying drawings, in all cases, as shown in Figure 1, as the bone cement hardened it could be seen that the mixture of TTCP and DCPD turned into hydroxyapatite. 2 shows that the hydroxyapatite substituted with CO 3 2- anion is formed as a cured product. In addition, it can be seen from FIG. 3 that in all cases, as hardening proceeds, needle-like hydroxyapatite is formed, and bone cement is hardened by crosslinking.
표 1
경화액pH 세팅 시간(분) 인젝션 시간(분)
초기 세팅 시간 마지막 세팅 시간 인젝션 가능 시작 시간 인젝션 가능 마지막 시간
비교예 8.6-9.0 8 13.5 4 8.5
실시예 1 8.0 8.5 14 4.5 8.5
2 7.5 9 14.5 5.5 10.5
3 7.0 10 15 6 14
4 6.5 12 17 7.5 17.5
5 6.1-6.4 15 21 9 21
Table 1
Curing solution pH Setting time (minutes) Injection time (minutes)
Initial setting time Last setting time Injectable Start Time Last time to inject
Comparative example 8.6-9.0 8 13.5 4 8.5
Example 1 8.0 8.5 14 4.5 8.5
2 7.5 9 14.5 5.5 10.5
3 7.0 10 15 6 14
4 6.5 12 17 7.5 17.5
5 6.1-6.4 15 21 9 21
이상에서는 본 발명을 특정의 바람직한 실시예를 예로 들어 도시하고 설명하였으나, 본 발명은 상기한 실시예에 한정되지 아니하며 본 발명의 정신을 벗어나지 않는 범위 내에서 당해 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에 의해 다양한 변경과 수정이 가능할 것이다.In the above, the present invention has been illustrated and described with reference to specific preferred embodiments, but the present invention is not limited to the above-described embodiments and the general knowledge in the technical field to which the present invention pertains without departing from the spirit of the present invention. Various changes and modifications will be made by those who possess.

Claims (9)

  1. 칼슘소스와 인산염소스로서 각각 적어도 1종의 화합물을 포함하는 건식성분,A dry ingredient comprising at least one compound as a calcium source and a phosphate source, respectively
    가용성 인산염과 유화제를 물에 용해하여 얻은 경화액, 및A curing liquid obtained by dissolving a soluble phosphate and an emulsifier in water, and
    상기 건식성분과 경화액 중 적어도 한쪽에 더 첨가되는 음이온을 포함하는 것을 특징으로 하는 음이온이 포함된 골 시멘트.Bone cement containing anion, characterized in that it comprises an anion further added to at least one of the dry component and the curing liquid.
  2. 제1항에 있어서,The method of claim 1,
    상기 음이온이 CO3 2-, SO4 2-, F-, PO4 3-, HPO4 2- 중에서 선택되는 것을 특징으로 하는 음이온이 포함된 골 시멘트.Bone cement containing anion, characterized in that the anion is selected from CO 3 2- , SO 4 2- , F , PO 4 3- , HPO 4 2- .
  3. 제1항 또는 제2항에 있어서,The method according to claim 1 or 2,
    상기 음이온이 상기 건식성분에 첨가되는 경우에는 분말상의 화합물 형태로 첨가되는 것을 특징으로 하는 음이온이 포함된 골 시멘트.When the anion is added to the dry ingredient bone cement containing anion, it is added in the form of a powdered compound.
  4. 제3항에 있어서,The method of claim 3,
    상기 분말상의 화합물은 탄산칼슘(CaCO3), 탄산나트륨(Na2CO3), 황산칼슘(CaSO4), 황산바륨(BaSO4), 불화소다(NaF) 중에서 선택되는 것을 특징으로 하는 음이온이 포함된 골 시멘트.The powdery compound includes an anion comprising calcium carbonate (CaCO 3 ), sodium carbonate (Na 2 CO 3 ), calcium sulfate (CaSO 4 ), barium sulfate (BaSO 4 ), and sodium fluoride (NaF). Bone cement.
  5. 제3항에 있어서,The method of claim 3,
    상기 화합물의 첨가량은 상기 건식성분 100 중량부에 대해 0.1 내지 30 중량부인 것을 특징으로 하는 음이온이 포함된 골 시멘트.The amount of the compound is bone cement containing anion, characterized in that 0.1 to 30 parts by weight based on 100 parts by weight of the dry ingredient.
  6. 제1항에 있어서,The method of claim 1,
    상기 음이온이 상기 경화액에 첨가되는 경우에는 가스(gas)형태로 첨가하거나 또는 상기 경화액에 용해되는 화합물 형태로 첨가하는 것을 특징으로 하는 음이온이 포함된 골 시멘트.When the anion is added to the curing liquid, the bone cement containing anion, characterized in that it is added in the form of a gas (gas) or in the form of a compound dissolved in the curing liquid.
  7. 제6항에 있어서, The method of claim 6,
    상기 화합물이 탄산칼슘(CaCO3), 탄산나트륨(Na2CO3), 황산칼슘(CaSO4), 황산바륨(BaSO4), 불화소다(NaF) 중에서 선택되며, 그 첨가량은 상기 경화액의 용매인 증류수의 부피를 100 ml로 할 경우 0.1 내지 30g 으로 하는 것을 특징으로 하는 음이온이 포함된 골 시멘트.The compound is selected from calcium carbonate (CaCO 3 ), sodium carbonate (Na 2 CO 3 ), calcium sulfate (CaSO 4 ), barium sulfate (BaSO 4 ), sodium fluoride (NaF), and the addition amount thereof is a solvent of the curing liquid. Bone cement containing anion, characterized in that when the volume of distilled water to 100 ml to 0.1 to 30g.
  8. 제6항에 있어서,The method of claim 6,
    상기 가스는 CO2 가스인 것을 특징으로 하는 음이온이 포함된 골 시멘트.The gas is bone cement containing anion, characterized in that the CO 2 gas.
  9. 제8항에 있어서,The method of claim 8,
    상기 CO2 가스의 첨가량은 상기 경화액의 pH변화량을 기준으로 pH 8.3 내지 pH 6.0 의 값을 갖도록 하는 것을 특징으로 하는 음이온이 포함된 골 시멘트.The addition amount of the CO 2 gas bone cement containing anion, characterized in that to have a value of pH 8.3 to pH 6.0 based on the pH change amount of the curing liquid.
PCT/KR2009/000426 2008-01-30 2009-01-29 Bone cement with anion WO2009096709A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0009815 2008-01-30
KR1020080009815A KR100981961B1 (en) 2008-01-30 2008-01-30 Anion substituted Injectable Bone Cement

Publications (2)

Publication Number Publication Date
WO2009096709A2 true WO2009096709A2 (en) 2009-08-06
WO2009096709A3 WO2009096709A3 (en) 2009-11-05

Family

ID=40913412

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/000426 WO2009096709A2 (en) 2008-01-30 2009-01-29 Bone cement with anion

Country Status (2)

Country Link
KR (1) KR100981961B1 (en)
WO (1) WO2009096709A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101294315B1 (en) * 2011-09-09 2013-08-07 한국기계연구원 Bone cement compositions and the method for preparing the same
KR101308952B1 (en) * 2012-11-28 2013-09-24 군산대학교산학협력단 COMPOSITION FOR BONE CEMENT CONTAINING NANO-SIZED β-TRICALCIUM PHOSPHATE AND PREPARING METHOD FOR THEREOF

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000045867A1 (en) * 1999-02-02 2000-08-10 Dr. H.C. Robert Mathys Stiftung Implant comprising calcium cement and hydrophobic liquid
US6206957B1 (en) * 1998-04-16 2001-03-27 Merck Patent Gesellschaft Mit Beschrankter Haftung Tricalcium phosphate-containing biocement pastes comprising cohesion promoters
WO2004000374A1 (en) * 2002-06-19 2003-12-31 Dr. H.C. Robert Mathys Stiftung Hydraulic cement based on calcium phosphate for surgical use
US6723334B1 (en) * 2000-03-01 2004-04-20 Iowa State University Research Foundation, Inc. Biologically compatible bone cements and orthopedic methods
WO2004094335A1 (en) * 2003-04-16 2004-11-04 Calcitec, Inc. Calcium phosphate cement, use and preparation thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060091714A (en) * 2003-04-16 2006-08-21 칼시텍, 인코포레이티드 Calcium phosphate cement, use and preparation thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6206957B1 (en) * 1998-04-16 2001-03-27 Merck Patent Gesellschaft Mit Beschrankter Haftung Tricalcium phosphate-containing biocement pastes comprising cohesion promoters
WO2000045867A1 (en) * 1999-02-02 2000-08-10 Dr. H.C. Robert Mathys Stiftung Implant comprising calcium cement and hydrophobic liquid
US6723334B1 (en) * 2000-03-01 2004-04-20 Iowa State University Research Foundation, Inc. Biologically compatible bone cements and orthopedic methods
WO2004000374A1 (en) * 2002-06-19 2003-12-31 Dr. H.C. Robert Mathys Stiftung Hydraulic cement based on calcium phosphate for surgical use
WO2004094335A1 (en) * 2003-04-16 2004-11-04 Calcitec, Inc. Calcium phosphate cement, use and preparation thereof

Also Published As

Publication number Publication date
WO2009096709A3 (en) 2009-11-05
KR20090083806A (en) 2009-08-04
KR100981961B1 (en) 2010-09-13

Similar Documents

Publication Publication Date Title
JP5801280B2 (en) Calcium phosphate cement
US6733582B1 (en) Brushite hydraulic cement stabilized with a magnesium salt
US7294187B2 (en) Rapid-hardening calcium phosphate cement compositions
US7258735B2 (en) Process for affecting the setting and working time of bioresorbable calcium phosphate cements
US8557038B2 (en) Dual-phase calcium phosphate cement composition
AU2002232811B2 (en) Calcium phosphate composition and method of preparing same
SE517168C2 (en) A composition for an injectable bone mineral replacement material
WO2010119953A1 (en) Calcium phosphate cement composite for bone filling, and kit thereof
Bermudez et al. Compressive strength and diametral tensile strength of some calcium-orthophosphate cements: a pilot study
US20130138114A1 (en) Calcium-based bone cement formula with enhanced non-dispersive ability
WO2009096709A2 (en) Bone cement with anion
KR20110087081A (en) High-injectable calcium based cement composition
JP4668172B2 (en) Premixed self-hardening bone graft paste
JP5518745B2 (en) Formulation for magnesium ammonium phosphate cement
JP2022030655A (en) Calcium Phosphate Composition
JPH07163651A (en) Hardening material for medicine and dentistry
JPH04348755A (en) Hydraulic calcium phosphate cement
JPH06285146A (en) Cement to be hardened for medical or dental use
JPH0523388A (en) Calcium phosphate porous cement
JPH06335521A (en) Reformed calcium phosphate powder and curable composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09705094

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09705094

Country of ref document: EP

Kind code of ref document: A2